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Abstract
Background: HIV-1-positive patients clear the human papillomavirus (HPV) infection less frequently than HIV-1-negative.
Datasets for estimating HPV clearance probability often have irregular measurements of HPV status and risk factors. A new
transitional probability-based model for estimation of probability of HPV clearance was developed to fully incorporate
information on HIV-1-related clinical data, such as CD4 counts, HIV-1 viral load (VL), highly active antiretroviral therapy
(HAART), and risk factors (measured quarterly), and HPV infection status (measured at 6-month intervals).
Methodology and Findings: Data from 266 HIV-1-positive and 134 at-risk HIV-1-negative adolescent females from the
Reaching for Excellence in Adolescent Care and Health (REACH) cohort were used in this study. First, the associations were
evaluated using the Cox proportional hazard model, and the variables that demonstrated significant effects on HPV
clearance were included in transitional probability models. The new model established the efficacy of CD4 cell counts as a
main clearance predictor for all type-specific HPV phylogenetic groups. The 3-month probability of HPV clearance in HIV-1-
infected patients significantly increased with increasing CD4 counts for HPV16/16-like (p,0.001), HPV18/18-like (p,0.001),
HPV56/56-like (p=0.05), and low-risk HPV (p,0.001) phylogenetic groups, with the lowest probability found for HPV16/16-
like infections (21.6061.81% at CD4 level 200 cells/mm
3,p ,0.05; and 28.0361.47% at CD4 level 500 cells/mm
3). HIV-1 VL
was a significant predictor for clearance of low-risk HPV infections (p,0.05). HAART (with protease inhibitor) was significant
predictor of probability of HPV16 clearance (p,0.05). HPV16/16-like and HPV18/18-like groups showed heterogeneity
(p,0.05) in terms of how CD4 counts, HIV VL, and HAART affected probability of clearance of each HPV infection.
Conclusions: This new model predicts the 3-month probability of HPV infection clearance based on CD4 cell counts and
other HIV-1-related clinical measurements.
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Introduction
HIV-1-positive women clear HPV infections 4–10 times more
slowly than HIV-1-negative, and HIV-1-infected patients with
CD4+ T-lymphocytes cell count (CD4) ,200 cells/mm
3 show the
slowest clearance [1,2]. Understanding the role of immunosup-
pression in risk of persistence of sexually transmitted human
papillomavirus (HPV) infection, a main risk factor for cervical
intraepithelial neoplasia and a central etiologic agent of cervical
cancer, and clarifying how this risk is modified by other factors
(such as co-infections, antiretroviral therapy, and behavioral
factors) is important for optimization of follow-up strategy [3].
Information from longitudinal studies about factors that affect the
probability of type-specific HPV clearance can be used to estimate
the impact of cervical cancer interventions. However, this is often
problematic because HPV persistence is loosely defined as
detection of the same HPV type at two or more subsequent visits,
ranging from 2 months to 7 years [4,5,6,7,8,9], and its probability
depends on intervals between the tests. Further, the analysis is
complicated by the possibility of co-infections with multiple HPV
types as well as by varying length of intervals between missing
measurements of HPV status. Analytical methods that can fully
utilize real-life heterogeneous data, specifically, clinical data that
are unevenly scheduled (for example, at 6 months for HPV and at
3-month intervals for HIV clinical data) could be useful in studies
of the factors having an impact on probability of clearance of HPV
infection.
Here, we describe a transition probability model for studying
the relationship between immune status (based on CD4 cell count)
and probability of HPV clearance in HIV-infected patients. The
Reaching for Excellence in Adolescent Care and Health (REACH)
dataset used in this study planned for measurement of HIV-1
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cohorts, this study had missing and irregular visit measurements:
only 82% of time intervals between measurements of HPV statuses
were performed as scheduled (i.e., every 6 months), while other
HPV tests were done at 3-, 9-, 12-, or other-month intervals.
Analyzing these data with standard techniques would require
multiple assumptions about the definition of HPV clearance and
censoring time for each individual for time-dependent predictors;
as a result, part of the dataset would not be utilized. We have
developed transition probability-based models and applied an
HPV/HIV co-infected cohort to estimate 3-month HPV clearance
probabilities while maximizing all available data for both HIV and
HPV in the estimations.
Materials and Methods
Data on 266 HIV-1-positive and 134 high-risk HIV-1-negative
adolescent females from the REACH cohort were analyzed. The
REACH study design and methods of quarterly follow up with
HIV-1 testing, immunophenotyping, HIV-1 RNA viral load (VL)
and collection of biological specimens, demographic and behav-
ioral factors, and other clinical data, along with incidence and
prevalence of HPV infections, have been previously described
[2,10,11]. Briefly, between 1996 and 2000, adolescents aged 12–
19 years who were HIV-1-positive and comparable at-risk HIV-1-
negative persons were recruited into a longitudinal study at 15
clinical sites in the United States. HIV-1-related clinical data and
risk factors were measured every 3 months. At enrollment and
every 6 months thereafter, cervical lavage samples were tested for
HPV infection by MY09/MY11/HMB01-based PCR and for 30
HPV type-specific probes with a chemiluminescent dot blot
procedure [12]. PCR-based HPV data were classified as follows:
negative; positive for specific HPV types; or ‘‘positive, type
unknown’’ (when the sample was positive for the generic probe but
not for specific HPV type). PCR amplification of a human b-
globin gene segment was used for internal DNA quality control,
and samples negative for this assay were excluded from the
analysis. For certain types of analyses, HPVs were categorized
according to phylogenetic patterns [2,13] into: 1) 16/16-like (16,
31, 52, 58, 67); 2) 18/18-like (18, 39, 45, 59, 26, 51); 3) 56/56-like
(56, 53, 66); and 4) low-risk (6, 11, 42, 44, 54, 40, 13, 32, 62, 72, 2,
57, 55). The highly active antiretroviral therapy (HAART) was
defined as a combination of two nucleoside reverse transcriptase
inhibitors and either a protease inhibitor (PI) or a non-nucleoside
reverse transcriptase inhibitor, or a zidovudine/lamivudine
combination regimen plus another antiretroviral drug. Data on
antiretroviral therapy were obtained through interviews and chart
reviews for current prescriptions, and adherence data were
obtained through interviews as previously described [14].
Ethics Statement
All the participants of the study provided written informed
consent in the parent study at the Adolescent Medicine HIV/
AIDS Research Network for the REACH project, and the UAB
Institutional Review Board approved this sub-study. The parent
study and this sub-study conformed to the procedures for informed
consent (parental permission was obtained wherever required)
approved by institutional review boards at all sponsoring
organizations and to human-experimentation guidelines set forth
by the United States Department of Health and Human Services.
Cox proportional hazard regression was used to test which
covariates have significant effects on probability of HPV clearance
for each of four phylogenetic HPV groups. First, an univariable
regression analysis was used for a wide spectrum of variables
including demographic characteristics, clinical exams, antiretrovi-
ral therapy, behavioral factors, and coinfections (as listed in
Table 1). From this, a subset of predictors with significant effects
was selected and considered in multivariable analysis. For this
analysis, SAS PROC PHREG (Cary, NC) was used.
The model developed in the present paper falls under the
general category of transitional Markov models and is referred to
as a transitional probability-based model. These kinds of approaches,
also known as regressive or conditional models, are used in
epidemiology for analyses of dependent binary observations
[15,16,17]. The model allows for estimating the probability of
changing HPV status in patients with specific HPV type, i.e., a
chance to clear HPV infection during the follow-up period. To
account for HIV-1-related clinical data such as CD4 counts, HIV-
1 VL, and other HIV-1-related factors, which were measured
every 3 months, HPV infection status was reconstructed for the
same time interval considering transition probabilities. The
transition probabilities were referred to as Pij(x), where i was
initial state of type-specific HPV infection (i~0 corresponded to
absence, and i~1to presence of type-specific HPV infection), and
j~0 and j~1 corresponded to the status of type-specific HPV
infection at the end of a 3-month period. Vector x denoted the set
of most influential predictors of HPV clearance probability, such
as CD4 count, HIV-1 VL, HAART, and HPV type [2,18]. For
example, the probability P10(x) corresponded to the situations
where HPV infection observed at a recent visit was cleared in 3
months.
With this model, the information about missed measurements at
odd visits can be reconstructed using the previous and forthcoming
measurements (see Figure 1A). The transition probability between
two subsequent visits with measured HPV status could be presented
as Pi0(xa)P0j(xb)zPi1(xa)P1j(xb), where i and j describe the HPV
status at the first and third visits, respectively. The status at a second
visit is unknown, and, therefore, the sum over two possible
intermediatestatescontributes totheobservedtransitionprobability
between two subsequent even visits. Parameters xa and xb in the
above formula denote the sets of respective predictors for transitions
between first-to-second and second-to-third visits, respectively. The
likelihoodfunctionistheproduct over all transferswithknownHPV
status. If data are taken exactly according to the cohort’s
measurement design, the likelihood is
L~P
n
P
kn
Pi0(xn
a)P0j(xn
b)zPi1(xn
a)P1j(xn
b)
  
ð1Þ
Here, ncovers all individuals in the dataset, kn—all transitions
between states with measured HPV virus status represented by
indices i and j in individualn, and xn
a and xn
b are the vectors of
predictors measured at the beginning of time period of respective
transition. The dependence of transition probabilities on predictors
are modeled in logistic regression style as:
P00(x)~
1
1zexp u0z
P
i b0ixi
   , P01(x)~1{P00(x)
P11(x)~
1
1zexp u1z
P
i b1ixi
   , P10(x)~1{P11(x)
ð2Þ
where intercepts u0 and u1 refer to logarithms of odds of changing
the type-specific HPV status for zeroth values of predictors, and
parameters b0i and b1i describe the effects of respective predictors
[19].
If the number of missed HPV status is 0 (zeroth) or varies from
two to five, the likelihood function could be generalized by
Probability of HPV Clearance
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with three missed HPV statuses (see Figure 1B), the contribution to
the likelihood function could be presented as:
X
m1
X
m2
X
m3
Pim1(xim1)Pm1m2(xm1m2)Pm2m3(xm2m3)Pm3j(xm3j),ð3Þ
where m1, m2, and m3 are unmeasured (0 or 1) HPV status in
three intermediate states. The set of observed transfers with
measured HPV statuses for a specific type of HPV virus or for
HPV group is the input dataset for likelihood maximization. Note
that CD4 count and HIV-1 VL also could have missing
measurements; however, the appearance of these missing variables
is not related to the study design, so we assume that they are
missing at random, and any standard approach for filling missing
data at random can be applied (e.g., imputation with the mean
conditional on observed values of other variables or simply linear
interpolation). Because in the REACH cohort, the fractions of
missing values of predictors of HPV clearance were relatively small
(about 2% for CD4 count in HIV-1-positive patients, about 5% for
HIV-1 VL, and about 1% for HAART), no notable impact of
specific scheme of their filling was expected. The reported results
were obtained using a linear interpolation to fill missing values in
the predictors (but not HPV) status.
To test the different hypotheses regarding the possible effects of
different potential predictors on probability of HPV clearance, a
two-stage approach was designed. The two-stage approach
complemented the advantages of methods used at each stage such
as nonparametric estimates of hazard ratios in the Cox model and
opportunities for evaluating 3-month probabilities for models (1) –
(3). The comparison of the results obtained from both approaches
allows for validating the properties of the new method. At the first
stage, the effects were evaluated using the Cox proportional hazard
model, and then the variables that demonstrated significant effects
on HPV clearance in the Cox analysis were included in the logistic
type models (substantively specified below). Note, the results can be
obtained only under specific assumptions that are necessary to
identify the times of HPV incidence and clearance/censoring.
Table 1. Demographic, behavioral, and clinical characteristics of adolescent female study participants from the REACH cohort.
Variable HIV-1-positive HIV-1-negative OR (95% CI)
Number of patients N=262 N=134 -
Age, years
1 16.8 (1.1) 16.6 (1.2) -
Number of visits per patient
1 11.0 (4.88) 8.7 (4.36)
{ -
Number of visits per patient with measured HPV status
1 5.6 (2.5) 4.7 (2.6)
{ -
Race
2
African Americans
Caucasians
Others
206 (78.6%)
15 (5.7%)
41 (15.6)%
92 (68.7%)
12 (9.0%)
30 (22.4%)
1.79 (0.81–3.98)
{
Referent
1.09 (0.45–2.67)
Baseline CD4+ T cell count, cells/mm
31 535.2 (263.6) 896.5 (258.9)
{ -
Number of lifetime sexual partners
2
,6
6–15
.15
81 (30.9%)
104 (39.7%)
77 (29.4%)
54 (40.3%)
43 (32.1%)
37 (27.6%)
Referent
1.61 (0.98–2.85)
1.39 (0.82–2.34)
Ever smoked cigarettes
2
Never smoked
Smoked ($100 cigarettes)
33 (12.6%)
205 (78.2%)
20 (14.9%)
101 (75.4%)
0.81 (0.44–1.49)
Referent
Trichomonas infection
2
Negative
Positive
219 (83.6%)
34 (13.0%)
128 (95.5%)
{
2( 1 . 5 % )
Referent
9.93 (2.35–42.03)
{
Gonorrhea infection
2
Negative
Positive
208 (79.4%)
22 (8.4%)
104 (77.6%)
9( 6 . 7 % )
Referent
1.22 (0.54–2.75)
Chlamydia infection
2
Negative
Positive
182 (69.5%)
50 (19.1%)
90 (67.2%)
26 (19.4%)
Referent
0.95 (0.56–1.62)
HIV VL, logarithm
1 3.44 (1.01) - -
Currently taking ART medications
2
Not on ART drugs
Mono or combination therapy without PI
Combo therapy with PI
125 (47.7%)
101 (38.5%)
35 (13.4%)
--
ART therapy ever used
2
No ART was used
Mono or combination therapy without PI
Combo therapy with PI
ART regimen unknown
98 (37.4%)
105 (40.0%)
57 (21.8%)
2 (0.8%)
--
Notes:
1 – results are presented as mean (SD);
2 – number of cases (percent);
{–p ,0.05 for the difference between HIV-1-positive and HIV-1-negative: continuous variables were analyzed by general linear model, and categorical were analyzed by
chi-square;
{–p ,0.05 for the difference with the referent group; continuous variables were analyzed by general linear model, and categorical were analyzed by PROC LOGISTIC.
doi:10.1371/journal.pone.0030736.t001
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to treat missing data on unknown HPV status. There is no
consensus in literature about the choice of specific assumptions in
these situations. Based on the published studies, our set of
assumptions included: 1) time of HPV incidence was 90 days
before the first exam with positive HPV status; 2) patient was
Figure 1. Reconstruction of information about the missed measurements when one HPV status is unknown (Figure 1A) or several
(e.g., three) HPV statuses in a raw are missed (Figure 1B). Here, x denotes the set of predictors of HPV clearance probability, such as CD4
count, HIV-1 VL, HAART, and HPV type. When one HPV measurement is unknown (Figure 1A), i and j describe the HPV status at the first and third
visits, respectively, and parameters xa and xb denote the sets of predictors for transitions between first-to-second and second-to-third visits,
respectively. The probability of changing HPV status from the first (i.e., known) state of HPV infection i to the status of HPV infection at the second
visit (i.e., unknown) is Pi0(xa) when HPV status at the second visit is negative (i.e., ‘‘0’’) or Pi1(xa) when it is positive (i.e., ‘‘1’’). Respectively, at the third
visit (with measured/known HPV status) HPV status j can be defined as P0j(xb) when at the second visit it supposed to be HPV-negative, and P1j(xb)
when at the second visit it supposed to be HPV-positive. The sum over two possible intermediate states contributes to the total transition probability:
so, the transition probability between two subsequent visits with measured HPV status could be presented as Pi0(xa)P0j(xb)zPi1(xa)P1j(xb). When
three subsequent HPV status are unknown (Figure 1B), there are eight different combinations of HPV statuses in these states, each denoted by m1,
m2, and m3 as unmeasured HPV statuses which can be 0 or 1). Therefore, the transition probability between states with known HPV statuses is
calculated as three-fold sum over all combinations of HPV statuses in these three unmeasured states.
doi:10.1371/journal.pone.0030736.g001
Probability of HPV Clearance
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30736removed when a time period between measurements exceeded 450
days; 3) when no time period between measurements exceeded 450
days, the clearance time was the time of the first (of the two
subsequent) negative exams, ignoring any missing visits; 4) when the
last exam was positive, the censoring time was the time of this exam
plus 180 days; and 5) when the last exam was negative (after the
positive), the censoring time was the time of this exam.
The approach used at the second stage (i.e., the formalism based
on eq. (1–3)) does not require these assumptions. All logistic-type
models described the probability of a 3-month HPV clearance for
different predictors using the base equation 2; their parameters
were estimated using the likelihood described in equation 1 and
generalized in the style of equation 3. The CD4 count parameter
was selected to be tested by the model as a main predictor of HPV
clearance in HIV-1-positive patients based on multiple studies
[2,20,21]—the base model (M1) had it as a main parameter and
an argument of the exponent for the model in equation 2 was
u1zb1:CD4. Then, additional models were developed, extending
the base model as follows:
M2 —includes the effect of the presence of HIV-1 infection on
intercept of u1zb1:CD4zb2:jHIV, where jHIV is the binary
variable characterizing the HIV-1 seropositivity (jHIV~1)o r
HIV-1 seronegativity (jHIV~0). While the base model M1 is
applied separately for HIV-1-positive and HIV-1-negative pa-
tients, the M2 as well as the M3 models are designed to investigate
whether and how specifically the effect of CD4 counts on HPV
clearance probability is influenced by the presence of HIV-1
infection, which may have an effect on HPV clearance beyond the
CD4 counts effect (e.g., this effect could be further compared with
the patients with other immunodeficiencies such as those with
organ transplants or inherited immune disorders).
M3 —extends the M2 model by including the possible
interference of the effects of HIV-1 seropositivity and CD4 count
on HPV clearance u1zb1:CD4zb2:
CD4:jHIV. This model evaluates the modifying effect of CD4 on
HPV clearance by the presence of HIV-1-infection.
M4 —in HIV-1-infected patients, it introduces CD4 count as a
squared parameter in P11(x) (the exponent argument is
u1zb1:CD4zb2:CD42)t ot e s tt h ea s s u m p t i o na b o u tn o n -
linearity (squared CD4) in interrelations between CD4 count
and HPV clearance probability in HIV-1-positive patients.
M5 —in HIV-1-positive patients, the effect of CD4 count is
described as a piecewise-linear interpolation with an arbitrary set
xk, k~1,...,K of K nodes (i.e., CD4 count values at which the
linear functions are joined):
u1z
X K
k~1
~ b bk{1{u1z ~ b bk{~ b bk{1
   CD4{xk{1
xk{xk{1
  
Ix k{1vCD4ƒxk ðÞ :
where I(:) is the indicator function and ~ b b0~u1; parameters ~ b bk
referring to the logarithms of odds of changing the HPV status for
CD4~xk. This model tests whether different shapes of interrela-
tions between CD4 counts and probability of HPV clearance are
possible in HIV-1-positive patients at a very low (,200 cells/mm
3),
low (200–499 cells/mm
3), and normal range of CD4 counts.
M6 —includes the logarithm of HIV-1 VL (u1zb1:CD4z
b2:log(VL)) to evaluate the effect of HIV-1 VL on probability of
HPV clearance in HIV-1-positive patients controlling the level of
CD4 count.
M7 —investigates the effects of HAART that include PIs on the
intercept u1zb1:CD4zb2:jHAART, where jHAART is a binary
variable of HAART; jHAART~1 when HAART (with PI) was
applied at the time of the visit. This model tests whether HAART
with PIs may have an additional effect on interrelations between
CD4 count and probability of HPV clearance in HIV-1-infected
patients.
The nonlinear optimization techniques as implemented in
PROC NLP in SAS 9.2 (Cary, NC) were used for the likelihood
maximization in all these models to estimate a 3-month probability
of HPV clearance. For the majority of calculations, the intercept
and the effects of the predictors were chosen as model parameters
and estimated with the standard errors (SEs). Because of the
functional relation between parameter b (which describes the
effects of predictor of clearance) and the clearance probability for a
certain value of predictor, the latter can be used as a model
parameter instead of b. Estimation of this model using the Proc
NLP allows for evaluating its standard error.
Results
The main characteristics of studied patients are listed in Table 1.
The average age of HIV-1-infected adolescent females were 16.8
(61.1) years old, and 78.6% of them were African Americans. On
average, they had about 11 HIV-1 status-related visits/examina-
tions per patient (quarterly); however, HPV data were collected
only biannually, so during half of these visits. Table 2 provides
detailed descriptions of incident and prevalent HPV infections:
among oncogenic HPVs, HPV16, 31, 52, and 67 (HPV16/16-like
group), HPV59 and 26 (HPV18/18-like group), and HPV56 and
53 (HPV56/56-like group) were more often (p,0.05) registered in
HIV-1-infected than HIV-1-negative patients.
The results of the Cox proportional hazard analysis for HIV-1-
infected adolescent females are shown in Table 3. No significant
HRs were obtained for such parameters as having ,6o r.15
lifetime sexual partners, ever being a smoker, or being infected
with Trichomonas vaginalis or Neisseria gonorrhea. CD4 count was a
consistent predictor for clearance of HPV16/16-like, 18/18-like,
and low-risk groups. For these HPV groups, a significantly higher
probability of HPV clearance was at CD4 levels higher than 500
cells/mm
3 (compared with those at ,500 cells/mm
3); the
difference was especially pronounced for CD4 categorical cutout
at 200 cells/mm
3. For HIV-1 VL, significant effect on HPV
clearance (for all except HPV56/56-like group) was observed only
without CD4 count as a second parameter (in the univariable
analysis). While being on HAART was a significant predictor of
HPV16/16-like clearance only, being on HAART with PI
significantly increased probability of clearance of 16/16-like, 18/
18-like, and low-risk HPV infection. Also, being infected with
Chlamydia trachomatis could be a positive predictor for low-risk HPV
clearance.
Sensitivity analysis was performed to check the stability of HRs
estimated by the Cox model. In many cases, the HRs essentially
shifted when assumptions changed: e.g., the effect of CD4 being
.200cells/mm
3 changed forHPV16/16-likeinfectionfrom 1.68to
1.86, and from 2.53 to 3.07 (still remaining significant) when 365
days were used in assumptions #2a n d#3 instead of 450 days.
Another example is the changes of the HAART effect from 1.77 to
2.03 for HPV16/16-like infection, which remained highly signifi-
cant while using 270 days instead of 450 in these assumptions.
The results obtained from the basic model and from the models
describing the effects of HIV-1 VL and HAART (with PIs) are
shown in Table 4, and the results obtained from all models (M1–
Probability of HPV Clearance
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Variable HIV-1-positive (n=262) HIV-1-negative (n=134)
HPV infection Non-infected
Prevalent
infection
Incident
infection Non-infected
Prevalent
infection
Incident
infection
HPV16/16-like HPV16 177 (67.6%) 45 (17.2%) 40 (15.3%) 108 (80.6%) 7 (5.2%) 19 (14.2%)
HPV31/33/35 166 (63.4%) 39 (14.9%) 57 (21.8%) 105 (78.4%) 12 (9.0%) 17 (12.7%)
HPV52 197 (75.2%) 31 (11.8%) 34 (13%) 117 (87.3%) 4 (3.0%) 13 (9.7%)
HPV58 182 (69.5%) 43 (16.4%) 37 (14.1%) 102 (76.1%) 12 (9.0%) 20 (14.9%)
HPV67 240 (91.6%) 2 (0.8%) 20 (7.6%) 131 (97.8%) 1 (0.7%) 2 (1.5%)
HPV18/18-like HPV18 199 (76.0%) 20 (7.6%) 43 (16.4%) 112 (83.6%) 10 (7.5%) 12 (9.0%)
HPV39 232 (88.5%) 11 (4.2%) 19 (7.3%) 128 (95.5%) 1 (0.7%) 5 (3.7%)
HPV45 218 (83.2%) 13 (5.0%) 31 (11.8%) 119 (88.8%) 3 (2.2%) 12 (9.0%)
HPV51 221 (84.4%) 7 (2.7%) 34 (13.0%) 115 (85.8%) 4 (3.0%) 15 (11.2%)
HPV59/68/70 170 (64.9%) 28 (10.7%) 64 (24.4%) 105 (78.4%) 7 (5.2%) 22 (16.4%)
HPV26/69 221 (84.4%) 6 (2.3%) 35 (13.4%) 124 (92.5%) 3 (2.2%) 7 (5.2%)
HPV56//56-like HPV56 215 (82.1%) 20 (7.6%) 27 (10.3%) 123 (91.8%) 3 (2.2%) 8 (6.0%)
HPV53/66 142 (54.6%) 40 (15.3%) 79 (30.2%) 103 (76.9%) 5 (3.7%) 26 (19.4%)
HPV low-risk HPV6/11/42/44 178 (67.9%) 32 (12.2%) 52 (19.8%) 109 (81.3%) 11 (8.2%) 14 (10.4%)
HPV54/40 191 (72.9%) 10 (3.8%) 61 (23.3%) 114 (85.1%) 4 (3.0%) 16 (11.9%)
HPV13/32 222 (84.7%) 2 (0.8%) 38 (14.5%) 127 (94.8%) 1 (0.7%) 6 (4.5%)
HPV62/72 224 (85.5%) 5 (1.9%) 33 (12.6%) 128 (95.5%) 1 (0.7%) 5 (3.7%)
HPV2/57 252 (96.2%) 1 (0.4%) 9 (3.4%) 134 (100%) 0 0
HPV55 250 (95.4%) 0 12 (4.6%) 131 (97.8%) 0 3 (2.2%)
Notes: results are presented as number of cases (percent);
{–p ,0.05 for the difference between HIV-1-positive and HIV-1-negative; categorical variables were analyzed by chi-square.
doi:10.1371/journal.pone.0030736.t002
Table 3. Hazard ratios for HPV infection clearance probability for HIV-1-infected adolescent females from the REACH cohort,
univariable and multivariable Cox proportional hazard regression (results are presented with 95% CIs).
Parameter HPV16/16-like HPV18/18-like HPV56/56-like HPV low risk
Univariable Multivariable Univariable Multivariable Univariable Multivariable Univariable Multivariable
CD4/100
(per each
100cells/mm
3
increase)
1.08(1.06,1.10)
{ 1.15(1.08,1.23)
{ 1.05(1.03,1.08)
{ 1.34(1.24,1.45)
{ ns ns 1.11(1.08,1.14)
{ 1.24(1.12,1.36)
{
CD4 level
$200 cells/mm
3
(vs. ,200
cells/mm
3)
1.68(1.32,2.14)
{ n/a 1.80(1.40,2.31)
{ n/a ns n/a 2.53(1.81,3.53)
{ n/a
CD4 level
$500 cells/mm
3
(vs. ,500
cells/mm
3)
1.65(1.42,1.91)
{ n/a 1.70(1.45,1.98)
{ n/a ns n/a 2.11(1.74,2.57)
{ n/a
HIV-1 VL 0.82(0.76,0.88)
{ ns 0.79(0.73,0.86)
{ ns ns ns 0.74(0.67,0.81)
{ ns
HAART ns 1.42(1.22,1.66)
{ ns ns ns ns ns ns
HAART with PI 1.57(1.33,1.84)
{ 1.77(1.50,2.08)
{ 1.75(1.47,2.08)
{ 1.79(1.50,2.13)
{ ns ns 1.68(1.36,2.08)
{ 1.82(1.47,2.27)
{
Any HPV
infection
at baseline
ns ns ns ns ns ns ns ns
Chlamydia
trachomatis
ns ns ns ns ns ns 1.69(1.33,2.14)
{ 1.60(1.26,2.02)
{
Note:
{p,0.05;
{p,0.001; ns - not significant; n/a – not applicable.
doi:10.1371/journal.pone.0030736.t003
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in HIV-1-infected patients increased with increasing CD4 level for
all HPV groups: parameter b11 (the log odds ratio, describing the
effect of CD4 count on HPV clearance) was 1.15 (0.27) for
HPV16/16-like (p,0.001), 1.58 (0.36) for HPV18/18-like
(p,0.001), 0.72 (0.38) for HPV56/56-like (p=0.059), and 1.5
(0.41) for low-risk HPVs (p,0.001). HPV16/16-like infection was
least likely to clear at low CD4 cell count (,200 cells/mm
3) than
other HPV groups (see Figure. 2): a probability of HPV16/16-like
clearance was 21.60 (1.81)% vs. 27.40 (2.38)% for HPV18/18-like,
29.96 (3.30)% for HPV56/56-like, and 26.60 (2.79)% for low-risk
HPVs (see Table 5). The interrelations between probability of
clearance of oncogenic HPVs and CD4 likely had a piecewise
shape for CD4 count ,500 cells/mm
3 (see Table S1). The effect of
HIV-1 VL was minor on HPV16/16-like clearance (p=0.061)
and significant for low-risk HPV (p,0.05) (the M6 model,
Table 4). A minor effect of HAART with PIs was observed on
HPV16/16-like (p=0.060) clearance (the M7 model, Table 4).
When two oncogenic groups of HPV infections—HPV16/16-
like and HPV18/18-like—were analyzed for each HPV type
separately, both groups showed heterogeneity in terms of how
probability of type-specific HPV clearance was affected by CD4
counts, HIV VL, and HAART with PI (see Table 6): while lower
clearance probability was registered for HPV16/16-like than for
the 18/18-like group (p,0.05). Interestingly, HPV16 and HPV18
alone had an equal chance to be cleared at all CD4 levels
examined: i.e., 20.29(3.76)% and 18.16(4.04)% at CD4 level 200
cells/mm
3, 26.63(3.19)% and 28.66(4.0)% at CD4 level 400 cells/
mm
3, and 34.12(3.49)% and 42.12(6.24)% at CD4 level 600 cells/
mm
3, for HPV16 and HPV18, respectively). The effect of HIV-1
VL was significant for clearance of HPV58 (16-like group) and
HPV59 (18-like group), and the effect of HAART (with PIs) was
significant for HPV16 clearance. In average, HPV67 had a higher
probability to be cleared than the other 16/16-like HPV types:
e.g., 64.11 (15.72)% vs. 25.76 (1.48)% at CD4 level 400 cells/mm
3
(p,0.05). Likewise, HPV18 had the lowest probability to be
cleared (18.16 (4.04)%), and HPV26 the highest (42.12 (8.39)%)
than other 18/18-like HPV types at CD4 level 200 cells/mm
3
compared to the group at average (27.40 (2.38)%), p,0.05.
Discussion
The longitudinal studies of HPV infection are important for
determining the covariates and outcomes associated with HPV
persistence, which leads to the development of cancer. Tradition-
ally, the rate of HPV clearance are usually compared in HIV-1-
positive patient subgroups based on baseline CD4 counts (such as
Figure 2. The 3-month HPV type-specific probability of
clearance depending on CD4 T-lymphocytes in HIV-1-positive
adolescent girls from the REACH cohort.
doi:10.1371/journal.pone.0030736.g002
Table 4. CD4 T-lymphocyte counts (basic model M1), HIV VL (M6 model), and HAART with PI (M7 model) effects on probability of
HPV clearance, by phylogenetic HPV group, in HIV-1-infected adolescent females, REACH cohort.
HPV type Model u00 (SE) b00 (SE)
a u11 (SE) b11 (SE)
a Additional parameter in the model (SE)
16/16-like M1 23.560.15** 20.1460.25 21.5260.15** 1.1560.27** ––
M6 23.4760.17** 20.0960.28 20.760.47* 0.7960.35** 20.1760.09*
M7 23.560.14** 20.1360.25 21.6560.17** 1.2360.27** 0.3360.18*
18/18-like M1 23.3860.14** 20.4760.25* 21.2960.18** 1.5860.36** ––
M6 23.4860.16** 20.260.28 20.9860.64* 2.160.66** 20.1460.12
M7 23.3860.13** 20.4760.25** 21.3860.18** 1.5860.36** 0.2960.21*
56/56-like M1 22.8260.19** 20.5960.35* 20.9960.22** 0.7260.38* ––
M6 23.0560.24** 20.3560.4 20.9060.67* 0.760.51 20.0560.13
M7 22.8260.19** 20.5860.35* 21.0360.25** 0.7460.38** 0.0960.25
Low risk M1 23.6960.15** 20.2660.27 21.3160.21** 1.560.41** ––
M6 23.8260.17** 0.0560.29 20.1360.64 0.9360.51* 20.2660.13**
M7 23.6960.15** 20.2760.27 21.4260.22** 1.5460.41** 0.3360.24
Note:
*0.05#p,0.1;
**p,0.05.u00, b00, u11, and b11 are related to the parameters in equation (2)
a– the units of b00 and b11 are 1000/[C], where [C] are the units of CD4 cell counts, i.e., cells/mm
3.
SEs were obtained by re-estimating the model in which probability at specific value of CD4 cell count was chosen as a model parameter instead of b1i.
doi:10.1371/journal.pone.0030736.t004
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3) using Kaplan-Meier curves
and Cox proportional hazards models [1,2,22,23]. The new
method developed in this study is based on the logistic-type model
and allows for prediction of future HPV status, conditional on its
current status and the measurements of factors that are potential
predictors of an HPV clearance event; i.e., CD4 count was
considered to be a main predictor with HIV-1 VL and HAART
(with PI) as additional predictors. The model parameters were
estimated by maximizing the likelihood function constructed as the
product over transfers with known HPV statuses (measured every
6 months) and HIV-1-related covariates (measured every 3
months). Similar to Kong et al. [17], our methodology is based
on conditional probabilities that take into account multiple
correlations between individual outcomes measured longitudinal-
ly. However, the developed method extends the opportunities of
approaches by Kong as well as several other researchers
[1,2,24,25] by reconstructing between-the-measurements HPV
statuses (i.e., presence or absence of HPV infection). This
approach allows for inclusion of the whole longitudinal dataset,
thus increasing the accuracy of prediction of probability of HPV
clearance without making multiple assumptions about how the
time of incidence, clearance, and censoring events could be
reconstructed (as it is required for Kaplan-Meier and Cox
analyses). The shorter intervals accessible in our method allow
for taking into account the dynamics of potential predictors, which
could change quickly (such as CD4 count, HIV-1 VL, and
HAART regimen). This model allows for calculating the clearance
probability with subsequent confirmation in another 3 months—
P100(x)—by transferring the probabilities such as P100(x)~P10(x)
P00(x), thus corresponding to the routine definition of HPV
clearance when the absence of HPV type-specific infection is
required for two subsequent visits. Opposite to the Cox model, in
which HRs are estimated for time-dependent covariates, the
developed approach allows us to estimate the transition probability
and evaluate its standard errors. Since the developed model
provides the hazard function for probability of HPV infection
clearance, the respective survival function and characteristics of
time-to-clearance distribution also can be evaluated: e.g., time to
clearance (in months) could be estimated as 3=P10(x), and a
median of HPV clearance time as 3log(2)=P10(x)&2:1=P10(x).
The approaches utilizing the generalized estimating equation
(GEE)—they take into account the mutual correlations in
Table 5. Probability of HPV clearance (in %, 6SE) at specific CD4 levels, by phylogenetic HPV group, in HIV-1-positive adolescent
females, REACH cohort.
CD4 cell (cells/mm
3) HPV16/16-like HPV18/18-like HPV56/56-like Low-risk HPV
200 21.6061.81 27.4062.38* 29.9663.30* 26.6062.79*
500 28.0361.47 37.7762.08* 34.6662.51* 36.2462.50*
750 34.1962.24 47.4263.57* 38.8363.50 45.2664.11*
1000 40.9363.69 57.2765.44* 43.1765.45 54.6066.28*
1500 55.2266.84 74.7467.46* 52.0969.95 71.8069.06*
Note: *The difference with HPV16/16-like type is significant (p,0.05).
doi:10.1371/journal.pone.0030736.t005
Table 6. CD4 T-lymphocyte counts (basic model M1), HIV VL (M6 model), and HAART (M7 model) effects on HPV clearance
probability, HPV type-specific, in HIV-1-positive adolescent females, REACH cohort.
HPV type M1 (basic model): CD4 effect
M6 model:
HIV VL effect,
M7 model:
HAART(PI) effect
u11 (SE) b11 (SE)
a
HPV16/16-like group HPV16 21.72(0.33)** 1.78(0.56)** ns 0.99(0.38)**
HPV31 21.55(0.32)** 0.97(0.55)* 20.14(0.17) 0.01(0.34)
HPV52 21.42(0.31)** 1.28(0.56)** 20.25(0.2) 0.38(0.38)
HPV58 21.54(0.28)** 0.82(0.48)* 20.53(0.22)** 0.001(0.39)
HPV67 ns
b ns 28.46(8.3) 0.65(1.16)
HPV16/16-like 21.52(0.15)** 1.15(0.27)** 20.17(0.09)* 0.33(0.18)*
HPV18/18-like group HPV18 22.1(0.42)** 2.97(0.89)** 20.37(0.28), p=0.188 0.56(0.47)
HPV39 20.78(0.58) 1.97(1.24) ns 0.06(0.75)
HPV45 21.66(0.5)** 3.03(1.13)** 0.03(0.24) 20.26(0.57)
HPV51 21.41(0.53)** 1.61(1.05) 0.62(0.39)* 20.15(0.71)
HPV59 21.12(0.31)** 0.86(0.56)* 20.43(0.2)** 0.62(0.36)*
HPV26 20.49(0.51) 0.87(1.10) 20.08(0.4) 0.22(0.65)
HPV18/18-like 21.29(0.18)** 1.58(0.36)** 20.14(0.12) ns
Note: * 0.05#p,0.1; ** p,0.05. u00, b00, u11, and b11 are related to the parameters in equation (2).
a– the units of b00 and b11 are 1000/[C], where [C] are the units of CD4 cell counts, i.e., cells/mm
3.; b – non-significant.
SEs were obtained by re-estimating the model in which probability at specific value of CD4 cell count was chosen as a model parameter instead of b1i.
doi:10.1371/journal.pone.0030736.t006
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allowing individuals to have their own characteristics (i.e.,
distributed in a population)—could be used to further enrich the
developed base model; Xue et al. [26] recently reviewed the series
of approaches that can be used for similar generalizations.
In both approaches, a transitional probability-based model and
Cox regression model, CD4 count was a significant predictor of
clearance of all phylogenetic HPV groups in HIV-1-infected
adolescent females; also, certain effects of HAART (with PI) on
clearance of HPV16/16-like and HPV18/18-like infections were
observed. However, while in the Cox model, being HIV-1-infected
had a minor effect only on HPV56/56-like clearance, in the
transitional probability model, this factor was a significant
predictor of clearance of HPV16/16-like, HPV56/56-like, and
low-risk HPVs.
In immunodeficient patients, the mechanisms by which immune
deficiency increases the risk of persistence of HPV infection are
still poorly understood: some alterations in dendritic antigen-
presenting cells, Langerhans cells, and macrophages function, as
well as a deficient cytotoxic lymphocyte response to E6 and E7
proteins, might be the contributing factors [27,28]. The results
obtained from our study about the role of CD4 in HPV clearance
corroborate previous reports from the REACH cohort, as well as
several other studies on adult HIV-infected females
[1,2,29,30,31,32,33,34]. However, there is no agreement about
the role CD4 play in clearance of individual types of HPVs; e.g., in
several studies on both HIV-1-negative and HIV-1-positive
females, it has been shown that HPV16 infection has a lower
probability of clearance than other HPV types, possibly due to its
greater ability to escape immunologic surveillance [35,36,37],
while other studies did not demonstrate such a difference [38]. In
our study, a lower clearance probability was registered for the
HPV16/16-like than for the 18/18-like group, while HPV16 had
an equal-with-HPV18 chance to be cleared at both pathologic and
normal CD4 counts. The observed heterogeneity of phylogenetic
groups of HPV infection in terms of a probability of HPV
clearance may depend not only on CD4 counts and other
predictors measured at current time (such as HIV-1 VL and
HAART with PI), but also from the history of HPV type-specific
infection (e.g., from the time since HPV acquisition, which is an
unobserved variable), depending on a prevalent or incident type-
specific HPV infection. Further analysis could be performed using
non-Markov approaches to model unobserved time since HPV
acquisition.
HIV infection, independent of CD4 count, has also been
suggested to be a predictor of persistence of HPV infection in
HIV-1-positive women. This may imply an alternate mechanism
besides CD4, e.g., via alteration of the cytokine response to HPV
infection in the cervical mucus [2,39,40,41,42]. In our study, being
HIV-1-positive affected the probability of clearance of HPV16/
16-like, 18/18-like, and low-risk HPVs. In the REACH cohort–
based study by Moscicki et al. [2], when only subjects with normal
CD4 counts (i.e., $500 cells/mm
3) were considered, the
multivariable regression showed high significance of HIV status
as an independent predictor of HPV clearance event (HR=1.60,
p=0.012).
Currently, prognostic importance of high HIV-1 VL for HPV
clearance is not clear, but it likely increases the risk of persistence
of HPV infection at low CD4 cell counts [32,43]. In our study,
HIV-1 VL could affect the clearance of low-risk HPVs and certain
oncogenic HPVs (e.g., HPV58 and HPV59). The apparent impact
of HAART on HPV incidence, clearance, and persistence also is
not clear [11,23,32,44,45]. In our study, when HAART was
analyzed taking into account its PI component, a significant effect
was observed for HPV16, and minor effects were observed for
HPV16/16-like, HPV18/18-like, and HPV59. In vitro studies
have shown that specific PIs inhibit the ability of HPV16 E6 to
degrade p53 and selectively kill E-6-dependent cervical carcinoma
cells [46]. Previous crossover analyses in REACH suggested no
significant effect of HAART on HPV clearance [11]; however, the
effect of PI was not examined, as it is incorporated in this new
method. These results require further investigation with longer
follow up and more detailed analysis of HAART/PI history and
dose/exposure.
The observation on C. trachomatis increasing probability of
clearance of low-risk HPV falls in with the results from animal
studies about potential role of interferon-c as local ‘‘protector’’
against other (i.e., non-Chlamydia) infections [47,48]. Oncogenic
HPV types could be strong enough to avoid this mechanism;
recently, it has been speculated that C. trachomatis could have effect
on oncogenic HPV types [49].
The results of this study have several limitations. While the
prevalence and incidence of HPV infections among HIV-1-positive
adolescents in the REACH study is high [11], some of the
associations may have been limited by the relatively smaller sample
size of HIV-1-negative individuals along with the lower HPV
infection rate. Due to the populations served at the REACH
recruitment sites, young African-American women were a signifi-
cant proportion of the population; therefore, the results may not be
fully generalized to other populations. Also, the interrelations
described in this study were obtained on a cohort of young
adolescent girls with relatively short histories of HIV-1 infections,
who are generally healthy and whose immune response to the
infection may differ from older women; for example, it has been
shown in several studies that older age was associated with higher
risk of HPV persistence in both HIV-infected and HIV-uninfected
women [24,50]. Regarding the approach, the simple version of the
model was intentionally chosen as a base model, resulting in some
limitations; e.g., there was no distinction between the effects of
incident infection and re-infection, no correlations between
clearance of distinct HPV types in one individual were modeled,
and the time after the incidence was not explicitly represented. Due
to the two-step design of the study, some variables which were
statistically insignificant were not included into the second step of
the analysis thus potentially compromising the robustness of the
model. Nevertheless, the limitations can be overcome by the
extensions of the proposed approach using approaches specifically
developed for analyses of HPV clearance [26] and those that were
successfully used in other related research areas, e.g., g-formula [16]
or a (binomial) stochastic process model [51,52,53].
In summary, our new model estimates a probability for HPV
clearance of type-specific HPV groups at a 3-month period by
coordinating uneven time scales of measurements on biannual
HPV status and other quarterly HIV-1-related clinical data and
risk factors.
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